睡眠呼吸暫停生物學標志物的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

張凌 ,  李慶云

上海交通大學醫學院附屬瑞金醫院呼吸科(上海 200025);

Corresponding?author：

李慶云, Email: liqingyun68@aliyun.com

Keywords：

DOI：

10.7507/1671-6205.2015031

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 張凌, 李慶云. 睡眠呼吸暫停生物學標志物的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(1): 117-123. doi: 10.7507/1671-6205.2015031 Copy

1.	Young T, Palm M, Dempsey J, et al.The occurrence of sleep-disordered breathing among middle-aged adults.N Engl J Med, 1993, 328:1230-1235.
2.	高維杰, 王彥, 孫玫, 等.持續氣道正壓通氣治療阻塞性睡眠呼吸暫停低通氣綜合征的依從性調查.中華結核和呼吸雜志, 2011, 34:68-69.
3.	Krieger J.Long-term compliance with nasal continuous positive airway pressure (CPAP) in obstructive sleep apnea patients and nonapneic snorers.Sleep, 1992, 15(6 Suppl):S42-S46.
4.	Sanders MH, Gruendl CA, Rogers RM.Patient compliance with nasal CPAP therapy for sleep apnea.Chest, 1986, 90:330-333.
5.	Weaver TE, Kribbs NB, Pack AI, et al.Night-to-night variability in CPAP use over first three months of treatment.Sleep, 1997, 20:278-283.
6.	孫士波, 郝青林, 徐鷗, 等.長期自動調節壓力持續正壓通氣治療阻塞性睡眠呼吸暫停低通氣綜合征的臨床觀察.國際呼吸雜志, 2012, 32:201-203.
7.	李慶云.慢性間歇低氧與氧化應激.中華結核和呼吸雜志, 2009, 32:646-647.
8.	郭雪玲, 劉輝國.慢性間歇低氧血管內皮功能障礙與氧化應激的關系研究進展.中華結核和呼吸雜志, 2012, 35:203-206.
9.	Simiakakis M, Kapsimalis F, Chaligiannis E, et al.Lack of effect of sleep apnea on oxidative stress in obstructive sleep apnea syndrome (OSAHS) patients.PLoS ONE, 2012, 7:e39172.
10.	Carpagnano GE, Kharitonov SA, Resta O, et al.Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients.Chest, 2002, 122:1162-1167.
11.	Carpagnano GE, Kharitonov SA, Resta O, et al.8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy.Chest, 2003, 124:1386-1392.
12.	Weiss JW, Liu Y, Li X, et al.Nitric oxide and obstructive sleep apnea. Respir Physiol Neurobiol, 2012, 184:192-196.
13.	Ip MS, Lam B, Chan LY, et al.Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure.Am J Respir Crit Care Med, 2000, 162:2166-2171.
14.	Alonso-Fernández A, García-Río F, Arias MA, et al.Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea:a randomized trial.Thorax, 2009, 64:581-586.
15.	Del Ben M, Fabiani M, Loffredo L, et al.Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment.BMC Pulm Med, 2012, 12:36.
16.	Karamanll H, ?ol D, Ugur KS, et al.Influence of CPAP treatment on airway and systemic inflammation in OSAS patients.Sleep Breath, 2014, 18:251-256.
17.	Okur HK, Pelin Z, Yuksel M, et al.Lipid peroxidation and paraoxonase activity in nocturnal cyclic and sustained intermittent hypoxia.Sleep Breath, 2013, 17:365-371.
18.	Papandreou C, Schiza SE, Tzatzarakis MN, et al.Effect of Mediterranean diet on lipid peroxidation marker TBARS in obese patients with OSAHS under CPAP treatment:a randomised trial.Sleep Breath, 2012, 16:873-879.
19.	Lam JC, Tan KC, Lai AY, et al.Increased serum levels of advanced glycation end-products is associated with severity of sleep disordered breathing but not insulin sensitivity in non-diabetic men with obstructive sleep apnoea.Sleep Med, 2012, 13:15-20.
20.	Kotani K, Kimura S, Komada I, et al.Continuous positive air pressure treatment reduces serum advanced glycation end products in patients with obstructive sleep apnoea syndrome:a pilot study.Prim Care Respir J, 2011, 20:336-337.
21.	Guo Q, Wang Y, Li QY, et al.Levels of thioredoxin are related to the severity of obstructive sleep apnea:based on oxidative stress concept.Sleep Breath, 2013, 17:311-316.
22.	Zhou W, Li S, Wan N, et al.Effects of various degrees of oxidative stress induced by intermittent hypoxia in rat myocardial tissues.Respirology, 2012, 17:821-829.
23.	Ruiz GA, Sánchez AA, Luque CE.Blood uric acid levels in patients with sleep-disordered breathing.Arch Bronconeumol, 2006, 42:492-500.
24.	Ryan S, McNicholas WT, Taylor CT.A critical role for p38 map kinase in NF-κB signaling during intermittent hypoxia/reoxygenation.Biochem Biophys Res Commun, 2007, 355:728-733.
25.	Williams A, Scharf SM.Obstructive sleep anea, cardiovascular disease, and inflammation-is NF-κB the key? Sleep Breath, 2007, 11:69-76.
26.	Yokoe T, Minoguchi K, Matsuo H, et al.Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.Circulation, 2003, 107:1129-1134.
27.	Can M, A?ikg?z S, Mungan G, et al.Serum cardiovascular risk factors in obstructive sleep apnea.Chest, 2006, 129:233-237.
28.	Punjabi NM, Beamer BA.C-reactive protein is associated with sleep disordered breathing independent of adiposity.Sleep, 2007, 30:29-34.
29.	Lui MM, Lam JC, Mak HK, et al.C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity.Chest, 2009, 135:950-956.
30.	Steiropoulos P, Tsara V, Nena E, et al.Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome.Chest, 2007, 132:843-851.
31.	Burioka N, Miyata M, Fukuoka Y, et al.Day-night variations of serum interleukin-6 in patients with severe obstructive sleep apnea syndrome before and after continuous positive airway pressure (CPAP).Chronobiol Int, 2008, 25:827-834.
32.	Sahlman J, Miettinen K, Peuhkurinen K, et al.The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea.J Sleep Res, 2010, 19:341-348.
33.	Barcelo A, Barbe F, Llompart E, et al.Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea.Am J Med, 2004, 117:118-121.
34.	Guilleminault C, Kirisoglu C, Ohayon MM.C-reactive protein and sleep-disordered breathing.Sleep, 2004, 27:1507-1511.
35.	Taheri S, Austin D, Lin L, et al.Correlates of serum C-reactive protein (CRP)-no association with sleep duration or sleep disordered breathing.Sleep, 2007, 30:991-996.
36.	Hotamisligil GS.Inflammatory pathways and insulin action.Int J Obes Relat Metab Disord, 2003, 27:53-55.
37.	Maury E, Brichard SM.Adipokine dysregulation, adipose tissue in flammation and metabolic syndrome.Mol Cell Endocrinol, 2010, 314:1-16.
38.	Arnardottir ES, Maislin G, Schwab RJ, et al.The interaction of obstructive sleep apnea and obesity on the inflammatory markers C-reactive protein and interleukin-6:The Icelandic Sleep Apnea Cohort.Sleep, 2012, 35:921-932.
39.	Alberti A, Sarchielli P, Gallinella E, et al.Plasma cytokine levels in patients with obstructive sleep apnea syndrome:a preliminary study.J Sleep Res, 2003, 12:305-311.
40.	Patel SR, Zhu X, Storfer-Isser A, et al.Sleep duration and biomarkers of inflammation.Sleep, 2009, 32:200.
41.	Steiropoulos P, Kotsianidis I, Nena E, et al.Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome.Sleep, 2009, 32:537-543.
42.	Ishida K, Kato M, Kato Y, et al.Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea.Chest, 2009;136:125-129.
43.	Murase K, Mori K, Yoshimura C, et al.Association between plasma neutrophil gelatinase associated lipocalin level and obstructive sleep apnea or nocturnal intermittent hypoxia.PloS ONE, 2013, 8:e54184.
44.	Cholidou KG, Kostakis ID, Manali ED, et al.Calprotectin:a protein related to cardiovascular risk in adult patients with obstructive sleep apnea.Cytokine, 2013, 61:917-923.
45.	何權瀛, 陳寶元, 張希龍.解讀阻塞性睡眠呼吸暫停與糖尿病專家共識.中國實用內科學, 2010, 30:703-704.
46.	Reichmuth KJ, Austin D, Skatrud JB, et al.Association of sleep apnea and typeⅡdiabetes:a population-based study.Am J Respir Crit Care Med, 2005, 172:1590-1595.
47.	Foster GD, Sanders MH, Millman R, et al.Sleep AHEAD Research Group.Obstructive sleep apnea among obese patients with type 2 diabetes.Diabetes Care, 2009, 32:1017-1019.
48.	高瑩慧, 何權瀛.睡眠呼吸暫停的診治首次納入美國臨床內分泌醫師學會糖尿病綜合治療方案指南.中華結核和呼吸雜志, 2011, 34:748.
49.	Aronsohn RS, Whitmore H, Van Cauter E, et al.Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes.Am J Respir Crit Care Med, 2010, 181:507-513.
50.	Lindberg E, Theorell-Hagl?w J, Svensson M, et al.Sleep apnea and glucose metabolism:a long-term follow-up in a community-based sample.Chest, 2012, 142:935-942.
51.	Shpirer I, Rapoport MJ, Stav D, et al.Normal and elevated HbA1C levels correlate with severity of hypoxemia in patients with obstructive sleep apnea and decrease following CPAP treatment.Sleep Breath, 2012, 16:461-466.
52.	Sharma SK, Agrawal S, Damodaran D, et al.CPAP for the metabolic syndrome in patients with obstructive sleep apnea.N Engl J Med, 2011, 365:2277-2286.
53.	Coughlin SR, Mawdsley L, Mugarza JA.Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome.Euro Heart J, 2004, 25:735-741.
54.	臧淑妃, 潘志杰, 李成江.代謝綜合征與阻塞性睡眠呼吸暫停低通氣綜合征獨立相關.中華內分泌代謝雜志, 2008, 24:400-403.
55.	Tan KC, Chow WS, Lam JC, et al.HDL dysfunction in obstructive sleep apnea.Atherosclerosis, 2006, 184:377-382.
56.	葉亮, 李敏, 陳聆.阻塞性睡眠呼吸暫停低通氣綜合征患者血脂及血液流變學的變化.中華結核和呼吸雜志, 2009, 32:926-930.
57.	Sharma SK, Kumpawat S, Goel A, et al.Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing.Sleep Med, 2007, 8:12-17.
58.	B rgel J, Sanner BM, Bittlinsky A, et al.Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels.Eur Respir J, 2006, 27:121-127.
59.	Ip MS, Lam KS, Ho C, et al.Serum leptin and vascular risk factors in obstructive sleep apnea.Chest, 2000, 118:580-586.
60.	Chin K, Shimizu K, Nakamura T, et al.Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy.Circulation, 1999, 100:706-712.
61.	Oktay B, Akbal E, Firat H, et al.CPAP treatment in the coexistence of obstructive sleep apnea syndrome and metabolic syndrome, results of one year follow up.Acta Clin Belg, 2009, 64:329-334.
62.	Davies RJ, Turner R, Crosby J, et al.Plasma insulin and lipid levels in untreated obstructive sleep apnoea and snoring, their comparison with matched controls and response to treatment.J Sleep Res, 1994, 3:180-185.
63.	Al-Shaer MH, Shammas NW, Lemke JH, et al.CPAP does not reduce high-sensitivity C-reactive protein in patients with coronary artery disease and obstructive sleep apnea.Int J Angiol, 2005, 14:129-132.
64.	Lattimore JL, Wilcox I, Skilton M, et al.Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation.Thorax, 2006, 61:491-495.
65.	Drager LF, Bortolotto LA, Figueiredo AC, et al.Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea.Am J Respir Crit Care Med, 2007, 176:706-712.
66.	Svatikova A, Wolk R, Magera MJ, et al.Plasma homocysteine in obstructive sleep apnoea.Eur Heart J, 2004, 25:1325-1329.
67.	Barceló A, Barbé F, de la Pe?a M, et al.Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment.Eur Respir J, 2006, 27:756-760.
68.	Lavie L, Perelman A, Lavie P.Plasma homocysteine levels in obstructive sleep apnea:association with cardiovascular morbidity.Chest, 2001, 120:900-908.
69.	Cintra F, Tufik S, D'Almeida V, et al.Cysteine:a potential biomarker for obstructive sleep apnea.Chest, 2011, 139:246-252.
70.	Alrajab S, Uysal A, Jenks C.Cysteine as a biomarker for obstructive sleep apnea.Chest, 2011, 140:268.
71.	丁少芳, 王麗, 蔣朝暉, 等.阻塞性睡眠呼吸暫停低通氣綜合征患者性激素水平的變化與分析.國際呼吸雜志, 2007, 27:1048-1050.
72.	Canguven O, Salepci B, Albayrak S, et al.Is there a correlation between testosterone levels and the severity of the disease in male patients with obstructive sleep apnea? Arch Ital Urol Androl, 2010, 82:143-147.
73.	Hoyos CM, Killick R, Yee BJ, et al.Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea:a randomized placebo-controlled trial.Clin Endocrinol, 2012, 77:599-607.
74.	Macrea MM, Martin TJ, Zagrean L.Infertility and obstructive sleep apnea:the effect of continuous positive airway pressure therapy on serum prolactin levels.Sleep Breath, 2010, 14:253-257.
75.	Shahar E, Redline S, Young T, et al.Hormone-replacement therapy and sleep-disordered breathing.Am J Respir Crit Care Med, 2003, 167:1186-1192.
76.	Mokhlesi B, Scoccia B, Mazzone T, et al.Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women.Fertil Steril, 2012, 97:786-791.
77.	Robinson GV, Pepperell JC, Segal HC, et al.Circulating cardiovascular risk factors in obstructive sleep apnoea:Data from randomized controlled trials.Thorax, 2004, 59:777-782.
78.	Phillips BG, Kato M, Narkiewicz K, et al.Increases in leptin levels, sympathetic drive and weight gain in obstructive sleep apnea.Am J Physiol Heart Circ Physiol, 2000, 279:H234-H237.
79.	Corsonello A, Malara A, Ientile R, et al.Leptin enhances adenosine diphosphate-induced platelet aggregation in healthy subjects.Obesity Res, 2002, 10:306.
80.	Rangemark C, Hedner JA, Carlson JT, et al.Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients.Sleep, 1995, 18:188-194.
81.	Takagi T, Morser J, Gabazza EC. The coagulation and protein C pathways in patients with sleep apnea.Lung, 2009, 187:209-213.
82.	Chihara Y, Chin K, Aritake K, et al.A urine biomarker for severe obstructive sleep apnoea patients:lipocaline-type prostaglandin D synthase.Eur Respir J, 2013, 42:563-574.
83.	Akpinar ME, Yigit O, Altundag A, et al.Salivary and serum myeloperoxidase in obstructive sleep apnea.J Otolaryngol Head Neck Surg, 2012, 41:215-221.
84.	Celec P, Hodosy J, Behuliak M, et al.Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure.Sleep Breath, 2012, 16:393-398.
85.	Raff H, Ettema SL, Eastwood DC, et al.Salivary cortisol in obstructive sleep apnea:the effect of CPAP.Endocrine, 2011, 40:137-139.
86.	Schmoller A, Eberhardt F, Jauch-Chara K, et al.Continuous positive airway pressure therapy decreases evening cortisol concentrations in patients with severe obstructive sleep apnea.Metabolism, 2009, 58:848-853.
87.	Dadoun F, Darmon P, Achard V, et al.Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men.Am J Physiol Endocrinol Metab, 2007, 293:466-474.
88.	Rudrappa S, Warren G, Idris I.Obstructive sleep apnoea is associated with the development and progression of diabetic retinopathy, independent of conventional risk factors and novel biomarkers for diabetic retinopathy. Br J Ophthalmol, 2012, 96:1535.
89.	Mayer P, Dematteis M, Pépin JL, et al.Peripheral neuropathy in sleep apnea.A tissue marker of the severity of nocturnal desaturation.Am J Respir Crit Care Med, 1999, 159:213-219.
90.	Othman M, Gordon SP, Iscoe S.Repeated inspiratory occlusions in anesthetized rats acutely increase blood coagulability as assessed by thromboelastography.Respir Physiol Neurobiol, 2010, 171:61-66.
91.	Kumagai T, Kasai T, Kate M, et al.Establishment of the cardio ankle vascular index in patients with obstructive sleep apnea.Chest, 2009, 136:779-786.

1. Young T, Palm M, Dempsey J, et al.The occurrence of sleep-disordered breathing among middle-aged adults.N Engl J Med, 1993, 328:1230-1235.
2. 高維杰, 王彥, 孫玫, 等.持續氣道正壓通氣治療阻塞性睡眠呼吸暫停低通氣綜合征的依從性調查.中華結核和呼吸雜志, 2011, 34:68-69.
3. Krieger J.Long-term compliance with nasal continuous positive airway pressure (CPAP) in obstructive sleep apnea patients and nonapneic snorers.Sleep, 1992, 15(6 Suppl):S42-S46.
4. Sanders MH, Gruendl CA, Rogers RM.Patient compliance with nasal CPAP therapy for sleep apnea.Chest, 1986, 90:330-333.
5. Weaver TE, Kribbs NB, Pack AI, et al.Night-to-night variability in CPAP use over first three months of treatment.Sleep, 1997, 20:278-283.
6. 孫士波, 郝青林, 徐鷗, 等.長期自動調節壓力持續正壓通氣治療阻塞性睡眠呼吸暫停低通氣綜合征的臨床觀察.國際呼吸雜志, 2012, 32:201-203.
7. 李慶云.慢性間歇低氧與氧化應激.中華結核和呼吸雜志, 2009, 32:646-647.
8. 郭雪玲, 劉輝國.慢性間歇低氧血管內皮功能障礙與氧化應激的關系研究進展.中華結核和呼吸雜志, 2012, 35:203-206.
9. Simiakakis M, Kapsimalis F, Chaligiannis E, et al.Lack of effect of sleep apnea on oxidative stress in obstructive sleep apnea syndrome (OSAHS) patients.PLoS ONE, 2012, 7:e39172.
10. Carpagnano GE, Kharitonov SA, Resta O, et al.Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients.Chest, 2002, 122:1162-1167.
11. Carpagnano GE, Kharitonov SA, Resta O, et al.8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy.Chest, 2003, 124:1386-1392.
12. Weiss JW, Liu Y, Li X, et al.Nitric oxide and obstructive sleep apnea. Respir Physiol Neurobiol, 2012, 184:192-196.
13. Ip MS, Lam B, Chan LY, et al.Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure.Am J Respir Crit Care Med, 2000, 162:2166-2171.
14. Alonso-Fernández A, García-Río F, Arias MA, et al.Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea:a randomized trial.Thorax, 2009, 64:581-586.
15. Del Ben M, Fabiani M, Loffredo L, et al.Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment.BMC Pulm Med, 2012, 12:36.
16. Karamanll H, ?ol D, Ugur KS, et al.Influence of CPAP treatment on airway and systemic inflammation in OSAS patients.Sleep Breath, 2014, 18:251-256.
17. Okur HK, Pelin Z, Yuksel M, et al.Lipid peroxidation and paraoxonase activity in nocturnal cyclic and sustained intermittent hypoxia.Sleep Breath, 2013, 17:365-371.
18. Papandreou C, Schiza SE, Tzatzarakis MN, et al.Effect of Mediterranean diet on lipid peroxidation marker TBARS in obese patients with OSAHS under CPAP treatment:a randomised trial.Sleep Breath, 2012, 16:873-879.
19. Lam JC, Tan KC, Lai AY, et al.Increased serum levels of advanced glycation end-products is associated with severity of sleep disordered breathing but not insulin sensitivity in non-diabetic men with obstructive sleep apnoea.Sleep Med, 2012, 13:15-20.
20. Kotani K, Kimura S, Komada I, et al.Continuous positive air pressure treatment reduces serum advanced glycation end products in patients with obstructive sleep apnoea syndrome:a pilot study.Prim Care Respir J, 2011, 20:336-337.
21. Guo Q, Wang Y, Li QY, et al.Levels of thioredoxin are related to the severity of obstructive sleep apnea:based on oxidative stress concept.Sleep Breath, 2013, 17:311-316.
22. Zhou W, Li S, Wan N, et al.Effects of various degrees of oxidative stress induced by intermittent hypoxia in rat myocardial tissues.Respirology, 2012, 17:821-829.
23. Ruiz GA, Sánchez AA, Luque CE.Blood uric acid levels in patients with sleep-disordered breathing.Arch Bronconeumol, 2006, 42:492-500.
24. Ryan S, McNicholas WT, Taylor CT.A critical role for p38 map kinase in NF-κB signaling during intermittent hypoxia/reoxygenation.Biochem Biophys Res Commun, 2007, 355:728-733.
25. Williams A, Scharf SM.Obstructive sleep anea, cardiovascular disease, and inflammation-is NF-κB the key? Sleep Breath, 2007, 11:69-76.
26. Yokoe T, Minoguchi K, Matsuo H, et al.Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.Circulation, 2003, 107:1129-1134.
27. Can M, A?ikg?z S, Mungan G, et al.Serum cardiovascular risk factors in obstructive sleep apnea.Chest, 2006, 129:233-237.
28. Punjabi NM, Beamer BA.C-reactive protein is associated with sleep disordered breathing independent of adiposity.Sleep, 2007, 30:29-34.
29. Lui MM, Lam JC, Mak HK, et al.C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity.Chest, 2009, 135:950-956.
30. Steiropoulos P, Tsara V, Nena E, et al.Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome.Chest, 2007, 132:843-851.
31. Burioka N, Miyata M, Fukuoka Y, et al.Day-night variations of serum interleukin-6 in patients with severe obstructive sleep apnea syndrome before and after continuous positive airway pressure (CPAP).Chronobiol Int, 2008, 25:827-834.
32. Sahlman J, Miettinen K, Peuhkurinen K, et al.The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea.J Sleep Res, 2010, 19:341-348.
33. Barcelo A, Barbe F, Llompart E, et al.Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea.Am J Med, 2004, 117:118-121.
34. Guilleminault C, Kirisoglu C, Ohayon MM.C-reactive protein and sleep-disordered breathing.Sleep, 2004, 27:1507-1511.
35. Taheri S, Austin D, Lin L, et al.Correlates of serum C-reactive protein (CRP)-no association with sleep duration or sleep disordered breathing.Sleep, 2007, 30:991-996.
36. Hotamisligil GS.Inflammatory pathways and insulin action.Int J Obes Relat Metab Disord, 2003, 27:53-55.
37. Maury E, Brichard SM.Adipokine dysregulation, adipose tissue in flammation and metabolic syndrome.Mol Cell Endocrinol, 2010, 314:1-16.
38. Arnardottir ES, Maislin G, Schwab RJ, et al.The interaction of obstructive sleep apnea and obesity on the inflammatory markers C-reactive protein and interleukin-6:The Icelandic Sleep Apnea Cohort.Sleep, 2012, 35:921-932.
39. Alberti A, Sarchielli P, Gallinella E, et al.Plasma cytokine levels in patients with obstructive sleep apnea syndrome:a preliminary study.J Sleep Res, 2003, 12:305-311.
40. Patel SR, Zhu X, Storfer-Isser A, et al.Sleep duration and biomarkers of inflammation.Sleep, 2009, 32:200.
41. Steiropoulos P, Kotsianidis I, Nena E, et al.Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome.Sleep, 2009, 32:537-543.
42. Ishida K, Kato M, Kato Y, et al.Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea.Chest, 2009;136:125-129.
43. Murase K, Mori K, Yoshimura C, et al.Association between plasma neutrophil gelatinase associated lipocalin level and obstructive sleep apnea or nocturnal intermittent hypoxia.PloS ONE, 2013, 8:e54184.
44. Cholidou KG, Kostakis ID, Manali ED, et al.Calprotectin:a protein related to cardiovascular risk in adult patients with obstructive sleep apnea.Cytokine, 2013, 61:917-923.
45. 何權瀛, 陳寶元, 張希龍.解讀阻塞性睡眠呼吸暫停與糖尿病專家共識.中國實用內科學, 2010, 30:703-704.
46. Reichmuth KJ, Austin D, Skatrud JB, et al.Association of sleep apnea and typeⅡdiabetes:a population-based study.Am J Respir Crit Care Med, 2005, 172:1590-1595.
47. Foster GD, Sanders MH, Millman R, et al.Sleep AHEAD Research Group.Obstructive sleep apnea among obese patients with type 2 diabetes.Diabetes Care, 2009, 32:1017-1019.
48. 高瑩慧, 何權瀛.睡眠呼吸暫停的診治首次納入美國臨床內分泌醫師學會糖尿病綜合治療方案指南.中華結核和呼吸雜志, 2011, 34:748.
49. Aronsohn RS, Whitmore H, Van Cauter E, et al.Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes.Am J Respir Crit Care Med, 2010, 181:507-513.
50. Lindberg E, Theorell-Hagl?w J, Svensson M, et al.Sleep apnea and glucose metabolism:a long-term follow-up in a community-based sample.Chest, 2012, 142:935-942.
51. Shpirer I, Rapoport MJ, Stav D, et al.Normal and elevated HbA1C levels correlate with severity of hypoxemia in patients with obstructive sleep apnea and decrease following CPAP treatment.Sleep Breath, 2012, 16:461-466.
52. Sharma SK, Agrawal S, Damodaran D, et al.CPAP for the metabolic syndrome in patients with obstructive sleep apnea.N Engl J Med, 2011, 365:2277-2286.
53. Coughlin SR, Mawdsley L, Mugarza JA.Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome.Euro Heart J, 2004, 25:735-741.
54. 臧淑妃, 潘志杰, 李成江.代謝綜合征與阻塞性睡眠呼吸暫停低通氣綜合征獨立相關.中華內分泌代謝雜志, 2008, 24:400-403.
55. Tan KC, Chow WS, Lam JC, et al.HDL dysfunction in obstructive sleep apnea.Atherosclerosis, 2006, 184:377-382.
56. 葉亮, 李敏, 陳聆.阻塞性睡眠呼吸暫停低通氣綜合征患者血脂及血液流變學的變化.中華結核和呼吸雜志, 2009, 32:926-930.
57. Sharma SK, Kumpawat S, Goel A, et al.Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing.Sleep Med, 2007, 8:12-17.
58. B rgel J, Sanner BM, Bittlinsky A, et al.Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels.Eur Respir J, 2006, 27:121-127.
59. Ip MS, Lam KS, Ho C, et al.Serum leptin and vascular risk factors in obstructive sleep apnea.Chest, 2000, 118:580-586.
60. Chin K, Shimizu K, Nakamura T, et al.Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy.Circulation, 1999, 100:706-712.
61. Oktay B, Akbal E, Firat H, et al.CPAP treatment in the coexistence of obstructive sleep apnea syndrome and metabolic syndrome, results of one year follow up.Acta Clin Belg, 2009, 64:329-334.
62. Davies RJ, Turner R, Crosby J, et al.Plasma insulin and lipid levels in untreated obstructive sleep apnoea and snoring, their comparison with matched controls and response to treatment.J Sleep Res, 1994, 3:180-185.
63. Al-Shaer MH, Shammas NW, Lemke JH, et al.CPAP does not reduce high-sensitivity C-reactive protein in patients with coronary artery disease and obstructive sleep apnea.Int J Angiol, 2005, 14:129-132.
64. Lattimore JL, Wilcox I, Skilton M, et al.Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation.Thorax, 2006, 61:491-495.
65. Drager LF, Bortolotto LA, Figueiredo AC, et al.Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea.Am J Respir Crit Care Med, 2007, 176:706-712.
66. Svatikova A, Wolk R, Magera MJ, et al.Plasma homocysteine in obstructive sleep apnoea.Eur Heart J, 2004, 25:1325-1329.
67. Barceló A, Barbé F, de la Pe?a M, et al.Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment.Eur Respir J, 2006, 27:756-760.
68. Lavie L, Perelman A, Lavie P.Plasma homocysteine levels in obstructive sleep apnea:association with cardiovascular morbidity.Chest, 2001, 120:900-908.
69. Cintra F, Tufik S, D'Almeida V, et al.Cysteine:a potential biomarker for obstructive sleep apnea.Chest, 2011, 139:246-252.
70. Alrajab S, Uysal A, Jenks C.Cysteine as a biomarker for obstructive sleep apnea.Chest, 2011, 140:268.
71. 丁少芳, 王麗, 蔣朝暉, 等.阻塞性睡眠呼吸暫停低通氣綜合征患者性激素水平的變化與分析.國際呼吸雜志, 2007, 27:1048-1050.
72. Canguven O, Salepci B, Albayrak S, et al.Is there a correlation between testosterone levels and the severity of the disease in male patients with obstructive sleep apnea? Arch Ital Urol Androl, 2010, 82:143-147.
73. Hoyos CM, Killick R, Yee BJ, et al.Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea:a randomized placebo-controlled trial.Clin Endocrinol, 2012, 77:599-607.
74. Macrea MM, Martin TJ, Zagrean L.Infertility and obstructive sleep apnea:the effect of continuous positive airway pressure therapy on serum prolactin levels.Sleep Breath, 2010, 14:253-257.
75. Shahar E, Redline S, Young T, et al.Hormone-replacement therapy and sleep-disordered breathing.Am J Respir Crit Care Med, 2003, 167:1186-1192.
76. Mokhlesi B, Scoccia B, Mazzone T, et al.Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women.Fertil Steril, 2012, 97:786-791.
77. Robinson GV, Pepperell JC, Segal HC, et al.Circulating cardiovascular risk factors in obstructive sleep apnoea:Data from randomized controlled trials.Thorax, 2004, 59:777-782.
78. Phillips BG, Kato M, Narkiewicz K, et al.Increases in leptin levels, sympathetic drive and weight gain in obstructive sleep apnea.Am J Physiol Heart Circ Physiol, 2000, 279:H234-H237.
79. Corsonello A, Malara A, Ientile R, et al.Leptin enhances adenosine diphosphate-induced platelet aggregation in healthy subjects.Obesity Res, 2002, 10:306.
80. Rangemark C, Hedner JA, Carlson JT, et al.Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients.Sleep, 1995, 18:188-194.
81. Takagi T, Morser J, Gabazza EC. The coagulation and protein C pathways in patients with sleep apnea.Lung, 2009, 187:209-213.
82. Chihara Y, Chin K, Aritake K, et al.A urine biomarker for severe obstructive sleep apnoea patients:lipocaline-type prostaglandin D synthase.Eur Respir J, 2013, 42:563-574.
83. Akpinar ME, Yigit O, Altundag A, et al.Salivary and serum myeloperoxidase in obstructive sleep apnea.J Otolaryngol Head Neck Surg, 2012, 41:215-221.
84. Celec P, Hodosy J, Behuliak M, et al.Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure.Sleep Breath, 2012, 16:393-398.
85. Raff H, Ettema SL, Eastwood DC, et al.Salivary cortisol in obstructive sleep apnea:the effect of CPAP.Endocrine, 2011, 40:137-139.
86. Schmoller A, Eberhardt F, Jauch-Chara K, et al.Continuous positive airway pressure therapy decreases evening cortisol concentrations in patients with severe obstructive sleep apnea.Metabolism, 2009, 58:848-853.
87. Dadoun F, Darmon P, Achard V, et al.Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men.Am J Physiol Endocrinol Metab, 2007, 293:466-474.
88. Rudrappa S, Warren G, Idris I.Obstructive sleep apnoea is associated with the development and progression of diabetic retinopathy, independent of conventional risk factors and novel biomarkers for diabetic retinopathy. Br J Ophthalmol, 2012, 96:1535.
89. Mayer P, Dematteis M, Pépin JL, et al.Peripheral neuropathy in sleep apnea.A tissue marker of the severity of nocturnal desaturation.Am J Respir Crit Care Med, 1999, 159:213-219.
90. Othman M, Gordon SP, Iscoe S.Repeated inspiratory occlusions in anesthetized rats acutely increase blood coagulability as assessed by thromboelastography.Respir Physiol Neurobiol, 2010, 171:61-66.
91. Kumagai T, Kasai T, Kate M, et al.Establishment of the cardio ankle vascular index in patients with obstructive sleep apnea.Chest, 2009, 136:779-786.

Chinese Journal of Respiratory and Critical Care Medicine

睡眠呼吸暫停生物學標志物的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content